Subject | Treatment | Metabolite Formation Clearances (ml · h−1 · kg−1 × 10−2) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(S)-6-OH
|
(R)-6-OH
|
(S)-7-OH
|
(R)-7-OH
|
(S)-8-OH
|
(R)-8-OH
| |||||||
1 | Control | 45 | 44 | 157 | 20 | 7 | 82 | |||||
100 mg Fl | 26 | 32 | 109 | 15 | 2 | 18 | ||||||
200 mg Fl | 27 | 25 | 77 | 11 | 3 | 29 | ||||||
300 mg Fl | 10 | 15 | 33 | 2 | 2 | 2 | ||||||
2 | Control | 55 | 98 | 193 | 39 | 7 | 186 | |||||
100 mg Fl | 32 | 51 | 119 | 20 | 3 | 36 | ||||||
200 mg Fl | 27 | 9 | 90 | 16 | 2 | 48 | ||||||
300 mg Fl | 18 | 32 | 49 | 3 | 2 | 5 | ||||||
3 | Control | 35 | 40 | 128 | 20 | 5 | 200 | |||||
100 mg Fl | 22 | 25 | 129 | 18 | 1 | 22 | ||||||
200 mg Fl | 18 | 17 | 64 | 8 | 2 | 39 | ||||||
300 mg Fl | 10 | 11 | 27 | 2 | 2 | 2 | ||||||
4 | Control | 54 | 51 | 227 | 29 | 8 | 113 | |||||
100 mg Fl | 23 | 28 | 136 | 22 | 0 | 21 | ||||||
200 mg Fl | 30 | 29 | 99 | 13 | 4 | 39 | ||||||
300 mg Fl | 23 | 31 | 73 | 4 | 1 | 4 | ||||||
5 | Control | 56 | 77 | 215 | 29 | 6 | 81 | |||||
100 mg Fl | 38 | 58 | 170 | 23 | 3 | 23 | ||||||
200 mg Fl | 34 | 56 | 124 | 18 | 4 | 40 | ||||||
300 mg Fl | 18 | 30 | 42 | 3 | 0 | 5 | ||||||
6 | Control | 74 | 80 | 277 | 37 | 11 | 124 | |||||
100 mg Fl | 36 | 38 | 158 | 25 | 3 | 23 | ||||||
200 mg Fl | 30 | 36 | 105 | 15 | 3 | 40 | ||||||
300 mg Fl | 22 | 26 | 64 | 5 | 0 | 7 | ||||||
7 | Control | 35 | 35 | 126 | 17 | 5 | 87 | |||||
100 mg Fl | 18 | 23 | 108 | 17 | 1 | 12 | ||||||
200 mg Fl | 17 | 20 | 56 | 8 | 1 | 25 | ||||||
300 mg Fl | 11 | 12 | 25 | 2 | 0 | 2 | ||||||
Mean (±S.D.)a | Control | 51(14) | 63(24) | 194(56) | 28(9) | 7(2) | 132(50) | |||||
100 mg Fl | 28(7) | 36(14) | 133(24) | 20(4) | 2(1) | 22(7) | ||||||
200 mg Fl | 26(6) | 33(15) | 88(24) | 13(4) | 3(1) | 37(8) | ||||||
|
300 mg Fl
|
16(6)
|
22(9)
|
45(18)
|
3(1)
|
1(1)
|
4(2)
|
Fl, fluconazole; OH, hydroxy.
↵ a The means of the clearances for each of the enantiomers across the control phase and the three fluconazole dose phases were significantly different (p < 0.001).